Sugi Predict

Sugi Predict / Targets / F8

F8

Coagulation factor VIII · P00451 · F8 on Sugi Atlas →

164 patent compounds predicted against F8, 126 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL13431399 SCHEMBL13431399 0.43 2/20
SCHEMBL12532640 SCHEMBL12532640 0.42 2/20
SCHEMBL15449488 SCHEMBL15449488 0.42 2/20
SCHEMBL12300300 SCHEMBL12300300 0.42 2/20
SCHEMBL13431408 SCHEMBL13431408 0.42 2/20
SCHEMBL12532633 SCHEMBL12532633 0.41 2/20
SCHEMBL12548173 SCHEMBL12548173 0.41 2/20
SCHEMBL13431400 SCHEMBL13431400 0.40 2/20
SCHEMBL17722679 SCHEMBL17722679 0.40 2/20
SCHEMBL13431401 SCHEMBL13431401 0.40 2/20
SCHEMBL15395278 SCHEMBL15395278 0.40 2/20
SCHEMBL15449547 SCHEMBL15449547 0.40 2/20
SCHEMBL15452227 SCHEMBL15452227 0.40 2/20
SCHEMBL15452229 SCHEMBL15452229 0.40 2/20
SCHEMBL15452230 SCHEMBL15452230 0.40 2/20
SCHEMBL15452233 SCHEMBL15452233 0.40 2/20
SCHEMBL15452259 SCHEMBL15452259 0.40 2/20
SCHEMBL15452279 SCHEMBL15452279 0.40 2/20
SCHEMBL17771207 SCHEMBL17771207 0.40 2/20
SCHEMBL17771210 SCHEMBL17771210 0.40 2/20

Clinical trials — most relevant to F8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study) PHASE4RECRUITING
Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A PHASE4COMPLETED
A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab PHASE4ACTIVE_NOT_RECRUITING
Preventing Inhibitor Recurrence Indefinitely PHASE4UNKNOWN
An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A. PHASE3COMPLETED
A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors PHASE3COMPLETED
Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A PHASE3COMPLETED
A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A PHASE3ACTIVE_NOT_RECRUITING
rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study PHASE3COMPLETED
Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures PHASE3COMPLETED
Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study) PHASE2/PHASE3COMPLETED
An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery. PHASE3COMPLETED
Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A PHASE3COMPLETED
BAX 855 PK-guided Dosing PHASE3COMPLETED
A Study of BAX 888 in Male Adults With Severe Hemophilia A PHASE1/PHASE2COMPLETED
A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection PHASE2COMPLETED
Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B PHASE2COMPLETED
A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection PHASE1COMPLETED
Lentiviral FVIII Gene Therapy PHASE1RECRUITING
Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer EARLY_PHASE1WITHDRAWN
Genetic Influence of Genetic Factors Influencing the Desmopressin's Efficacy in Mild/Moderate Hemophilia A nanUNKNOWN
Patterns of Hemophilia Care in Assiut Children Patients nanUNKNOWN
Register of Patients With haEmophilia A tReated With Afstyla® nanCOMPLETED
Improved Factor VIII Inhibitor Evaluation nanWITHDRAWN
A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection nanUNKNOWN
Heparin Management During Cardiopulmonary Bypass in Children nanCOMPLETED
GAS-Hem Feasibility Study nanCOMPLETED
Cross-sectional Study on Prevalence of Coagulation Factors Deficiency in Assiut University Children Hospital nanUNKNOWN
A Study of TAK-660 in Surgical Procedures for People With Hemophilia A. nanCOMPLETED
Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a F8 binder may also engage these)

ProteinNameSimilarity
Q06194 — 1.000 Q06194 →
Q28107 — 1.000 Q28107 →
O18806 — 1.000 O18806 →
F5 Coagulation factor V 0.999 landscape →
P12263 — 0.998 P12263 →
Q9GLP1 — 0.997 Q9GLP1 →
O88783 — 0.995 O88783 →
Q58L91 — 0.985 Q58L91 →
Q58L90 — 0.985 Q58L90 →
P34822 — 0.983 P34822 →
O88422 — 0.983 O88422 →
P35054 — 0.983 P35054 →
Q593B6 — 0.982 Q593B6 →
F8W3R9 — 0.981 F8W3R9 →
Q7SZN0 — 0.981 Q7SZN0 →
Q7Z7M9 — 0.981 Q7Z7M9 →
A6NHS7 — 0.981 A6NHS7 →
Q9ZVI7 — 0.981 Q9ZVI7 →
E9Q6D8 — 0.980 E9Q6D8 →
Q9BQ16 — 0.980 Q9BQ16 →
Q9VLA1 — 0.980 Q9VLA1 →
Q9QJ17 — 0.980 Q9QJ17 →
Q8NEM8 — 0.980 Q8NEM8 →
O45879 — 0.980 O45879 →
P47984 — 0.980 P47984 →
Q04399 — 0.980 Q04399 →
Q0IHQ9 — 0.979 Q0IHQ9 →
Q9R097 — 0.979 Q9R097 →
Q8VCM7 — 0.979 Q8VCM7 →
O95393 — 0.979 O95393 →